Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Robert Reiter, M.D., M.B.A.
Robert Reiter, M.D., M.B.A.



General Information:

English, French, Spanish


Physician, Department of Urology, General Adult Urology, Urologic Oncology, Prostate Research and Treatment Program
Member, JCCC Cancer Molecular Imaging Program Area

Hospital Affiliation(s):

Ronald Reagan UCLA Medical Center


Urology, Baylor College of Medicine, 1991 - 1995
Urology, Baylor College of Medicine, 1990 - 1991
Urology, Stanford University Medical Center, 1989 - 1990
Internal Medicine, Stanford University Medical Center, 1988 - 1989
Medical Degree:
M.D., Stanford University School of Medicine, 1988
M.B.A., UCLA Anderson School of Management, 2007


Board Certification(s):
Urology, American Board of Urology, 1998

Contact Information:

(310) 794-7700 Genitourinary Oncology, Laparoscopic Surgery and Urology information and referral
(310) 206-6909 Genitourinary Oncology referring physician
(310) 206-5930 Laparoscopic Surgery referring physician
(310) 794-7700 Prostate Research and Treatment Program referring physician
(310) 794-7704 Prostate Research and Treatment Program information and referral - Nazy Zomorodian, N.P., Program Coordinator
(310) 206-0297 Prostate Research and Treatment Program information and referral - Lynn Keil, R.N., Program Coordinator

Practice Information:

Clinical Interest(s):
Bladder Cancer
Gene Therapy
Irritative Voiding
Kidney Cancer
Kidney General
Laparoscopic Surgery
Nerve Sparing Prostatectomy
Penile Cancer
Prostate Cancer
Prostate General
Prostate Nodules
Testicular Cancer
Testicular Mass-Pain
Ureteral Obstruction
Urinary Diversion
Urinary Obstruction

Scientific Interest(s):

Dr. Robert Reiter's laboratory interest is in the basic molecular biology of urologic cancers and the translation of these discoveries to the clinical care of patients. He has a busy surgical practice focused on prostate cancer and conducts numerous clinical trials for urologic malignancies.

Over the past few years, Reiter's laboratory has focused on three interrelated areas: the discovery of novel cell surface and secreted proteins associated with prostate cancer progression, the development of therapies directed against these targets and development of animal models of prostate and bladder cancer. A primary example of these three areas is Reiter's work related to prostate stem cell antigen (PSCA), a cell surface antigen which is overexpressed in a large percentage of prostate and bladder cancers. This gene was discovered by subtractive hybridization of xenografted prostate cancers developed at UCLA. Monoclonal antibodies against PSCA were generated and shown to inhibit prostate cancer in preclinical models.

Reiter and his colleagues are currently studying the mechanism by which these antibodies inhibit tumor formation and metastasis. The researchers have also used these antibodies to study epithelial lineages within the normal prostate, hypothesizing that PSCA may mark a lineage associated with prostate carcinogenesis. Finally, the researchers have asked whether the PSCA promoter can be used to target marker genes and oncogenes to the prostate and bladder.

Reiter's first study, in collaboration with Dr. Owen Witte's laboratory, demonstrated that the PSCA promoter can drive green fluorescent protein expression to a unique subset of prostate epithelial cells associated with prostate growth and cancer formation. He and his associates are currently expanding these studies to develop novel transgenic models of prostate (and bladder) cancer. The researchers continue to identify additional genes potentially important in prostate and bladder cancer progression, which they hope to put through similar paradigms as described for PSCA.

Selected Cancer-Related Publications:

Finley DS, Margolis D, Raman SS, Ellingson BM, Natarajan S, Tan N, Huang J, Reiter RE. Fine-tuning robot-assisted radical prostatectomy planning with MRI. Urol Oncol. 2013 Aug;31(6):766-75. doi: 10.1016/j.urolonc.2011.07.013. Epub 2011 Sep 9.

Tanaka H, Kono E, Tran CP, Miyazaki H, Yamashiro J, Shimomura T, Fazli L, Wada R, Huang J, Vessella RL, An J, Horvath S, Gleave M, Rettig MB, Wainberg ZA, Reiter RE. Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat Med. 2010 Dec;16(12):1414-20. Epub 2010 Nov 7

Hara T, Miyazaki H, Lee A, Tran CP, Reiter RE. Androgen receptor and invasion in prostate cancer. Cancer Res. 2008 Feb 15;68(4):1128-35.

Leyton JV, Olafsen T, Lepin EJ, Hahm S, Bauer KB, Reiter RE, Wu AM. Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors. Clin Cancer Res. 2008 Nov 15;14(22):7488-96.

Olafsen T, Gu Z, Sherman MA, Leyton JV, Witkosky ME, Shively JE, Raubitschek AA, Morrison SL, Wu AM, Reiter RE. Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody. J Immunother. 2007 May-Jun;30(4):396-405.